Retrospective data have shown a quite consistent benefit of the dabrafenib + trametinib combination treatment for BRAF V600E-positive NSCLC patients, such as our data, with an ORR and DCR of 53% and 85%, respectively, mPFS ranging from 5.0 to 17.5 months and mOS from 10.8 to 22.5 months [33,45,46]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.